Core Viewpoint - Sanofi has successfully completed the acquisition of Blueprint Medicines, enhancing its portfolio with a commercialized medicine and a promising pipeline focused on systemic mastocytosis and other KIT-driven diseases [1][6]. Group 1: Acquisition Details - The acquisition includes Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis in the US and EU [3][10]. - Sanofi also acquired elenestinib, a next-generation investigational medicine for systemic mastocytosis, currently undergoing a phase 2/3 clinical study [4]. - Additionally, BLU-808, an investigational oral KIT inhibitor, was part of the acquisition, targeting a range of inflammatory diseases [5]. Group 2: Financial Aspects - The tender offer for Blueprint's shares was completed on July 17, 2025, with all conditions satisfied [6]. - Sanofi financed the acquisition through cash on hand and proceeds from commercial paper issuances, indicating it will not significantly impact the company's financial guidance for 2025 [7]. - The acquisition is expected to be immediately accretive to gross margin and business operating income, as well as EPS after 2026 [7]. Group 3: Market Impact - Following the acquisition, Blueprint common stock will cease trading on the NASDAQ Global Select Stock Market as of July 18, 2025 [9]. - All shares not validly tendered will convert to a cash payment of $129.00 per share, plus potential contingent payments of up to $6.00 per share based on milestone achievements [8].

Core Viewpoint - Sanofi is set to acquire Blueprint Medicines for approximately $9.1 billion, enhancing its portfolio in rare immunological diseases and expanding its early-stage pipeline in immunology [2][5][6] Group 1: Acquisition Details - The acquisition includes Ayvakit/Ayvakyt (avapritinib), the only approved medicine for advanced and indolent systemic mastocytosis (SM), and a promising pipeline of advanced and early-stage immunology treatments [3][4] - Sanofi will pay $129.00 per share in cash, representing a premium of approximately 27% over Blueprint's closing price on May 30, 2025, and a total equity value of about $9.5 billion when including potential milestone payments [5][12] - The acquisition is expected to be completed in the third quarter of 2025, subject to customary closing conditions and regulatory approvals [13][14] Group 2: Financial Impact - The acquisition is immediately accretive to gross margin and is expected to positively impact business operating income and EPS after 2026 [14] - Ayvakit achieved net revenues of $479 million in 2024 and nearly $150 million in Q1 2025, reflecting year-on-year growth of over 60% compared to Q1 2024 [9] Group 3: Strategic Rationale - The acquisition aligns with Sanofi's strategic intent to strengthen its therapeutic areas and enhance its immunology pipeline, positioning the company as a leader in the field [6][8] - Blueprint's established presence among allergists, dermatologists, and immunologists is anticipated to bolster Sanofi's growth in immunology [3][4]